Biotech and Pharma

Cellectis jumps 14% on talks of sale to Pfizer

French CEO of Cellectis, a biotechnology company, Andre Choulika.
Patrick Kovarik | AFP | Getty Images

Shares of French biotech firm Cellectis popped more than 14 percent on a report that the company is talking with potential buyers.

The Financial Times reported that a source familiar with the situation said Pfizer had approached the company with a deal that could value Cellectis about $1.64 billion.

New York-based Pfizer declined comment to the FT, and the publication wrote that Cellectis did not immediately return comment.

Cellectis held its Nasdaq initial public offering in March, in which it reportedly raised more than $228 million.

Read the report on potential Cellectis talks from The Financial Times.